Wang Eric A, Broadwell Scott R, Bellavia Ross J, Stein Jeff P
Charlotte Radiology, Carolinas Medical Center, Charlotte, NC, USA.
J Gastrointest Oncol. 2017 Apr;8(2):266-278. doi: 10.21037/jgo.2016.11.08.
Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) often present at stages where patients have limited treatment options. Use of selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres has progressed as data increasingly speak to its utility in patients with both intermediate and late stage disease in these cancers. In anticipation of the pending completion of several prospective randomized controlled multicenter studies exploring the use of Y-90 resin microspheres in primary liver cancers, this article outlines mechanisms involved in SIRT administration and reviews key efficacy and safety data that are currently available in the literature involving use of this therapy in both HCC and ICC.
肝细胞癌(HCC)和肝内胆管癌(ICC)通常在患者治疗选择有限的阶段出现。随着越来越多的数据表明钇-90(Y-90)树脂微球在这些癌症的中期和晚期患者中的应用价值,选择性内放射治疗(SIRT)的使用取得了进展。鉴于几项探索Y-90树脂微球在原发性肝癌中应用的前瞻性随机对照多中心研究即将完成,本文概述了SIRT给药所涉及的机制,并回顾了目前文献中关于该疗法在HCC和ICC中应用的关键疗效和安全性数据。